Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × Flucytosine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 6 Astrocytoma 6 Oligodendroglioma 4 Glioma 4 Brain Neoplasms 4 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Melanoma 1 Lymphoma 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 53 Lenalidomide 29 Cyclophosphamide 29 pomalidomide 27 Rituximab 27 Bortezomib 24 venetoclax 23 fludarabine 21 Paclitaxel 19 carfilzomib 18 Gemcitabine 18 Cisplatin 15 Carboplatin 15 pembrolizumab 14 daratumumab 14 Docetaxel 12 Calcium Dobesilate 12 Azacitidine 12 obinutuzumab 11 ibrutinib 11 Cytarabine 11 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 Injections 9 durvalumab 8 cemiplimab 8 blinatumomab 8 Doxorubicin 8 Cetuximab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡